Open AccessP830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG‐TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN‐LABEL EXTENSION
Author(s) -
Röth A.,
Egyed M.,
Ichikawa S.,
Ito Y.,
Kim J. S.,
Nagy Z.,
Obara N.,
Panse J.,
Schrezenmeier H.,
Sica S.,
Soret J.,
Usuki K.,
Yoon S.S.,
Benkali K.,
Buri M.,
Lundberg P.,
Patel H.,
Shinomiya K.,
Sreckovic S.,
Nishimura J.I.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846204.59341.a5
Subject(s) - eculizumab , paroxysmal nocturnal hemoglobinuria , medicine , hemoglobinuria , anemia , gastroenterology , chills , antibody , immunology , complement system